trial summary · NCT05487911
Cortical rTMS as a Treatment for Depression
Trial record from the TrialBase DB dataset, status RECRUITING, condition Major Depressive Disorder, sponsored by Baylor College of Medicine. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Depression is a leading cause of disability worldwide with a 19% lifetime prevalence in the United States. Dysfunctional reward processing is one of the core features of depression. Common treatments of depression include psychological therapies (e.g., cognitive behavioral therapy), medication (e.g., bupropion, sertraline) and psychological therapies and medication combined, but they may not address the function of the reward circuit in depression. These treatments often o not improve depressive symptoms in patients with depression who are classified as having treatment-resistant depression, and they may be unlikely to respond to further medication trials. Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation that enables us to selectively excite or inhibit neural activity. Multiple TMS pulses given consecutively are known as repetitive TMS (rTMS), and the primary clinical location for applying rTMS is the left dorsolateral prefrontal cortex (DLPFC) for treatment of depressive symptoms. Many of these studies have shown that rTMS to the DLPFC may result in decreased depressive symptoms, but is only partially effective (response and remission rates of 41.2 and 35.3%, respectively). This evidence supports the importance of evaluating the efficacy of rTMS in other brain regions, such as the orbitofrontal cortex (OFC), in the treatment of depressive symptoms rather than in the DLPFC.
Source record: https://clinicaltrials.gov/study/NCT05487911
Facts
| registry id | NCT05487911 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | not reported |
| study type | INTERVENTIONAL |
| lead condition | Major Depressive Disorder |
| sponsor | Baylor College of Medicine |
| sponsor class | OTHER |
| enrollment | 50 |
| start date | 2026-11-01 |
| primary completion | 2028-07-31 |
| completion | 2028-08-31 |
| results posted | not reported |
Conditions
- Major Depressive Disorder
- Opioid Use Disorder
- Suicidality
Interventions
- Repetitive Transcranial Magnetic Stimulation
Countries
- United States
Intervention types: DEVICE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.